205 related articles for article (PubMed ID: 17502752)
21. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
22. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
[TBL] [Abstract][Full Text] [Related]
24. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
25. Colonisation of fluoroquinolone-resistant Haemophilus influenzae among nursing home residents in southern Taiwan.
Chang CM; Lauderdale TL; Lee HC; Lee NY; Wu CJ; Chen PL; Lee CC; Chen PC; Ko WC
J Hosp Infect; 2010 Aug; 75(4):304-8. PubMed ID: 20356651
[TBL] [Abstract][Full Text] [Related]
26. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
Asbell PA; Colby KA; Deng S; McDonnell P; Meisler DM; Raizman MB; Sheppard JD; Sahm DF
Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Sulochana S; Rahman F; Paramasivan CN
J Chemother; 2005 Apr; 17(2):169-73. PubMed ID: 15920901
[TBL] [Abstract][Full Text] [Related]
28. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
29. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
Ozdek SC; Miller D; Flynn PM; Flynn HW
Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
[TBL] [Abstract][Full Text] [Related]
30. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Blondeau JM; Blondeau LD; Hesje C; Borsos S
J Chemother; 2006 Aug; 18(4):366-72. PubMed ID: 17024791
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
[TBL] [Abstract][Full Text] [Related]
32. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Naber KG; Hollauer K; Kirchbauer D; Witte W
Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
[TBL] [Abstract][Full Text] [Related]
34. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Stein GE; Schooley S
Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
[TBL] [Abstract][Full Text] [Related]
35. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Sirvent E; Ruiz M; Rodríguez JC; Royo G
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
[TBL] [Abstract][Full Text] [Related]
36. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
Jones RN; Biedenbach DJ; Erwin ME; Beach ML; Pfaller MA
J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
[TBL] [Abstract][Full Text] [Related]
37. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
Homma T; Hori T; Sugimori G; Yamano Y
Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
[TBL] [Abstract][Full Text] [Related]
39. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Brueggemann AB; Kugler KC; Doern GV
Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]